Issue Date: May 16, 2016
Pfizer, Wave team on metabolic therapy
Pfizer and Wave Life Sciences are joining to develop nucleic acid therapies targeting metabolic diseases. The partners will combine Wave’s stereopure drug development platform with Pfizer’s hepatic targeting technology for enhancing delivery to the liver. Pfizer will advance up to five programs from discovery through selection of clinical candidates, at which point it can license programs. Two targets have been declared. Wave will get $40 million up front and could take in $187 million if all five programs are successful.
- Chemical & Engineering News
- ISSN 0009-2347
- Copyright © American Chemical Society